Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 2/20 | 0.33 |
| ▸ | SKP1 | P63208 | 2/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406060 | 0.92 | DKK1 (0.42) | DKK1CNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2403823 | 0.91 | GSK3B (0.37) | DKK1CNR1FFAR4 | |
| SCHEMBL2408430 | 0.89 | CNR1 (0.42) | CNR1RAB9ASMN1; SMN2FFAR4 | |
| SCHEMBL2407363 | 0.88 | CNR1 (0.37) | CNR1NPC1RAB9AFFAR4AGTR2 | |
| SCHEMBL2407375 | 0.88 | CKS1B (0.40) | CNR1NPC1RAB9ASMN1; SMN2FFAR4 | |
| SCHEMBL2405737 | 0.88 | FFAR1 (0.36) | CNR1FFAR4ESR1ESR2CKS1B | |
| SCHEMBL2406117 | 0.88 | HSD11B1 (0.37) | FFAR4CKS1BSKP1SKP2AGTR2 | |
| SCHEMBL2406949 | 0.88 | CNR1 (0.39) | CNR1NPC1RAB9ASMN1; SMN2FFAR4 | |
| SCHEMBL2406016 | 0.88 | SYK (0.38) | CNR1NPC1RAB9ASMN1; SMN2FFAR4 | |
| SCHEMBL2405723 | 0.87 | FFAR4 (0.41) | CNR1FFAR4CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | DKK1 4247/4885CNR1 39/4885NPC1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.